TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07484022: Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Sponsor: Generate Biomedicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 37 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,382,304

Rescue Site Savings

+$911,064

Unlock Full NCT07484022 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07484022 Rescue Dossier →